The Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) has published its 2019 activity report, highlighting its key statistics, achievements and focusses for the year.
In their press release, ANSM said:
“The 2019 ANSM activity report demonstrates our central role in public health and highlights the diversity of our actions. These include assessment, inspection, surveillance, laboratory controls, decision-making and notification, as well as our contribution to legislative, regulatory developments and European and international activities. Whether these activities aim to ensure the safety of health products or facilitate access to therapeutic innovation, they are all carried out on a daily basis in the interests of patients and their safety. 2019 also saw the continuation and acceleration of our strategy to be more transparent with our stakeholders.”
Some of the key figures underlined in the report include that, in 2019, ANSM authorised 813 clinical trials, and granted 1016 marketing authorisations and 20 new Autorisations Temporaire d’Utilisation (ATUs).
Read the ANSM press release for further information.